Stock analysts at Goldman Sachs Group Inc. assumed coverage on shares of Amarin Co. plc (NASDAQ:AMRN) in a report issued on Tuesday, StockRatingsNetwork.com reports. The firm set a “neutral” rating on the stock.
Shares of Amarin Co. plc (NASDAQ:AMRN) opened at 6.58 on Tuesday. Amarin Co. plc has a 52-week low of $5.12 and a 52-week high of $14.30. The stock’s 50-day moving average is $6.07 and its 200-day moving average is $6.67. The company’s market cap is $1.136 billion.
Amarin Co. plc (NASDAQ:AMRN) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.38) by $0.12. The company had revenue of $5.50 million for the quarter. Analysts expect that Amarin Co. plc will post $-1.36 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at JPMorgan Chase & Co. cut their price target on shares of Amarin Co. plc (NASDAQ:AMRN) from $12.00 to $11.00 in a research note to investors on Friday. They now have an “overweight” rating on the stock. Separately, analysts at Aegis reiterated a “buy” rating on shares of Amarin Co. plc (NASDAQ:AMRN) in a research note to investors on Friday. They now have a $30.00 price target on the stock. Finally, analysts at SunTrust initiated coverage on shares of Amarin Co. plc (NASDAQ:AMRN) in a research note to investors on Wednesday, September 4th. They set a “buy” rating on the stock.
Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Amarin Co. plc currently has an average rating of “Buy” and an average price target of $13.54.
Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.